LACTOLOGY FOUNDATION

Mefenorex (ATC A08AA09) During Lactation

Mefenorex is a centrally acting anti-obesity agent classified as ATC A08AA09 and pharmacologically related to amphetamine. Its use during breastfeeding should generally be avoided because it is metabolized to amphetamine, has stimulant and dependence-related toxicological risks, and lacks adequate human data on concentrations in milk or outcomes in exposed infants.atcddd.fhi+2

ATC class and general pharmacology

ATC code: A08AA09
International nonproprietary name: Mefenorex
ATC group: A08A — Antiobesity preparations, excluding diet products
Pharmacological subgroup: A08AA — Centrally acting antiobesity products

Mefenorex is an amphetamine-related phenethylamine derivative historically used as an anorectic medicine in weight-management programmes. It is also described chemically as N-(3-chloropropyl)-amphetamine. Its intended therapeutic effect is appetite suppression, mediated by central nervous system stimulation and modulation of monoaminergic neurotransmission.atcddd.fhi+2

A defining pharmacological feature of mefenorex is its metabolic conversion to amphetamine. Human metabolic investigations have identified amphetamine as a principal metabolite, alongside p-hydroxymefenorex, p-hydroxyamphetamine, and p-hydroxy-m-methoxymefenorex. More extensive toxicological work has identified at least 13 metabolites, including amphetamine, supporting the characterization of mefenorex as an amphetamine-producing anorectic agent.link.springer+1

The pharmacodynamic consequences of this metabolism are clinically important. Amphetamine enhances catecholaminergic signalling in the central nervous system, particularly through noradrenergic and dopaminergic pathways. These actions may reduce hunger and food intake, but also generate psychostimulant, cardiovascular, neuropsychiatric, and dependence-related adverse effects. Mefenorex therefore should not be viewed as a pharmacologically neutral weight-loss medicine; it represents a parent-drug and active-metabolite exposure with amphetamine-like properties.

Toxicological profile

The toxicological profile of mefenorex arises from both the parent substance and its active amphetamine metabolite. This dual exposure is particularly relevant after repeated dosing, high-dose use, medication misuse, drug interactions, or impaired elimination.

Potential maternal adverse effects include:

• Insomnia, restlessness, agitation, anxiety, irritability, tremor, and headache.
• Reduced appetite, dry mouth, nausea, abdominal discomfort, and constipation.
• Tachycardia, palpitations, increased blood pressure, and other sympathomimetic cardiovascular effects.
• Sweating, hyperthermia, and reduced tolerance to physical exertion or dehydration.
• Mood changes, exacerbation of anxiety, and possible precipitation or worsening of psychotic symptoms in vulnerable individuals.
• Tolerance, misuse, dependence, and withdrawal symptoms after sustained stimulant exposure.

In severe intoxication, amphetamine-related toxicity may include pronounced agitation, confusion, hallucinations, severe hypertension, tachyarrhythmia, hyperthermia, seizures, rhabdomyolysis, and cardiovascular or neurological emergencies. Clinical risk may be amplified by concomitant use of other stimulants, high caffeine intake, nicotine, sympathomimetic decongestants, serotonergic medicines, or monoamine oxidase inhibitors.

Toxicological interpretation may be difficult. In controlled human excretion studies, only amphetamine—not mefenorex or its specific metabolites—was detectable from 32 to 68 hours after ingestion of an 80 mg dose. Amphetamine immunoassay screening remained positive for up to 68 hours. Thus, a positive amphetamine result may reflect prior mefenorex exposure, although confirmatory analytical testing for mefenorex-specific metabolites is necessary to distinguish it from direct amphetamine administration.pubmed.ncbi.nlm.nih

Mefenorex should be avoided in people with uncontrolled hypertension, significant cardiovascular disease, hyperthyroidism, glaucoma, severe anxiety, psychotic disorders, or a history of stimulant misuse or substance-use disorder. These precautions are especially relevant in the postpartum period, when sleep deprivation, anxiety, blood-pressure disorders, and mood vulnerability may be clinically significant.

Lactation pharmacology and infant exposure

No adequate published studies establish mefenorex concentrations in human milk, milk-to-plasma ratios, relative infant dose, infant serum concentrations, or neurodevelopmental outcomes after exposure through breastfeeding. Consequently, a reliable quantitative estimate of infant dose cannot be calculated.

The absence of direct lactation data must not be interpreted as evidence of safety. Several pharmacological characteristics support concern about potential infant exposure:

• Mefenorex is a small, centrally active, amphetamine-related compound.
• It produces amphetamine as a clinically active metabolite.
• Multiple metabolites are formed, and amphetamine may remain detectable after parent mefenorex and its specific metabolites are no longer measurable in biological samples.
• Amphetamine-related compounds have the potential to enter human milk and produce pharmacological effects in a vulnerable infant.link.springer+1

Amphetamine is of particular lactological relevance because it has central stimulant and sympathomimetic effects. If mefenorex or amphetamine reaches breast milk, an infant may be exposed to an agent capable of altering sleep, feeding, cardiovascular regulation, and neurobehaviour. The risk is more concerning in newborns, preterm infants, infants with low birth weight, and infants with hepatic, renal, neurological, or cardiac disease.

Potential signs of clinically meaningful infant stimulant exposure include:

• Irritability, unexplained crying, jitteriness, tremor, or an exaggerated startle response.
• Unusually prolonged wakefulness, reduced sleep, or disturbed sleep pattern.
• Poor latch, reduced feeding endurance, feeding refusal, vomiting, or reduced weight gain.
• Tachycardia, sweating, pallor, or other features of sympathetic stimulation.
• Rare but serious neurological manifestations, including marked agitation, abnormal movements, or seizures.

Indirect lactation effects are also plausible. Maternal appetite suppression, inadequate energy intake, dehydration, insomnia, and anxiety may reduce the mother’s capacity to sustain breastfeeding. Moreover, dopaminergic stimulation may theoretically suppress prolactin secretion and adversely affect milk synthesis, particularly before lactation is well established. No mefenorex-specific clinical evidence quantifies this effect; however, it adds to the rationale for avoiding the medicine while breastfeeding.

Lactological safety assessment and clinical recommendations

Overall lactological assessment: Avoid use during breastfeeding.

Mefenorex should not be considered compatible with routine breastfeeding. The assessment is driven by the lack of direct milk and infant-outcome data, its metabolism to amphetamine, its stimulant toxicology, the possibility of infant neurobehavioural and cardiovascular effects, and its potential to interfere with maternal wellbeing and milk production. The substance is formally classified among centrally acting anti-obesity medicines, and human studies confirm metabolite formation that includes amphetamine.atcddd.fhi+2

Clinical recommendations

1. Do not initiate mefenorex during lactation.
   Pharmacological weight-loss treatment with mefenorex should be deferred until breastfeeding has ended whenever possible, especially during exclusive breastfeeding and in the early postpartum period.
2. Prefer non-pharmacological postpartum weight management.
   Nutritionally adequate gradual weight reduction, individualized dietary counselling, postpartum-appropriate physical activity, sleep support, and evaluation for medical contributors to weight retention are preferred approaches.
3. Review an established exposure promptly.
   If a lactating patient is already taking mefenorex, the medicine should be reviewed promptly by the prescriber together with the infant’s paediatric clinician. Assessment should include maternal dose, duration, timing of the last dose, concurrent medicines or substances, maternal symptoms, infant age, prematurity, clinical condition, and the degree of breast-milk intake.
4. Do not depend on feed timing as a safety strategy.
   Breastfeeding immediately before a maternal dose, discarding one feed, or briefly delaying feeding should not be assumed to prevent exposure. The parent compound generates multiple metabolites, including amphetamine, and amphetamine may remain detectable after mefenorex is no longer identified.pubmed.ncbi.nlm.nih
5. Individualize interruption and resumption decisions.
   If clinically relevant exposure occurs, a clinician or poisons-information service should determine whether temporary interruption of breastfeeding is appropriate and when feeding may safely resume. If breastfeeding is temporarily paused, milk expression may be needed to preserve milk production and reduce engorgement, according to clinical advice.
6. Monitor the infant after known exposure.
   Observe for poor feeding, poor weight gain, irritability, tremor, sleep disturbance, pallor, sweating, increased heart rate, abnormal movements, or unusual lethargy. Seek urgent paediatric evaluation for marked agitation, persistent vomiting, breathing difficulty, fever, seizure-like activity, or suspected cardiovascular symptoms.
7. Avoid concurrent stimulant exposure.
   Maternal use of other stimulants, amphetamines, cocaine, excessive caffeine, nicotine, decongestants with sympathomimetic activity, or unregulated weight-loss products can increase maternal and infant risk and complicate assessment.